Perspective Therapeutics (CATX) Competitors $2.47 +0.02 (+0.82%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.44 -0.03 (-1.21%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CATX vs. AVNS, BFLY, CBLL, KIDS, BBNX, TMCI, DCTH, NPCE, CLPT, and TCMDShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Avanos Medical (AVNS), Butterfly Network (BFLY), CeriBell (CBLL), OrthoPediatrics (KIDS), Beta Bionics (BBNX), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), NeuroPace (NPCE), ClearPoint Neuro (CLPT), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Avanos Medical Butterfly Network CeriBell OrthoPediatrics Beta Bionics Treace Medical Concepts Delcath Systems NeuroPace ClearPoint Neuro Tactile Systems Technology Avanos Medical (NYSE:AVNS) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings. Does the media prefer AVNS or CATX? In the previous week, Avanos Medical had 7 more articles in the media than Perspective Therapeutics. MarketBeat recorded 12 mentions for Avanos Medical and 5 mentions for Perspective Therapeutics. Perspective Therapeutics' average media sentiment score of 1.31 beat Avanos Medical's score of 0.20 indicating that Perspective Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perspective Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, AVNS or CATX? Perspective Therapeutics has lower revenue, but higher earnings than Avanos Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvanos Medical$687.80M0.83-$61.80M-$8.53-1.45Perspective Therapeutics$1.43M127.91-$46.51MN/AN/A Do insiders and institutionals believe in AVNS or CATX? 95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 2.6% of Avanos Medical shares are held by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is AVNS or CATX more profitable? Avanos Medical has a net margin of 2.30% compared to Perspective Therapeutics' net margin of -4,096.66%. Avanos Medical's return on equity of 4.70% beat Perspective Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avanos Medical2.30% 4.70% 3.46% Perspective Therapeutics -4,096.66%-27.40%-23.16% Which has more volatility & risk, AVNS or CATX? Avanos Medical has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Do analysts recommend AVNS or CATX? Perspective Therapeutics has a consensus price target of $12.75, suggesting a potential upside of 416.19%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Avanos Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18 Does the MarketBeat Community prefer AVNS or CATX? Avanos Medical received 54 more outperform votes than Perspective Therapeutics when rated by MarketBeat users. However, 97.06% of users gave Perspective Therapeutics an outperform vote while only 55.77% of users gave Avanos Medical an outperform vote. CompanyUnderperformOutperformAvanos MedicalOutperform Votes8755.77% Underperform Votes6944.23% Perspective TherapeuticsOutperform Votes3397.06% Underperform Votes12.94% SummaryPerspective Therapeutics beats Avanos Medical on 10 of the 17 factors compared between the two stocks. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$182.91M$4.33B$5.53B$18.96BDividend YieldN/A39.93%5.11%4.01%P/E RatioN/A30.0322.5932.87Price / Sales127.9155.31401.3528.03Price / CashN/A51.0838.1817.52Price / Book0.936.056.774.47Net Income-$46.51M$68.71M$3.22B$1.02B7 Day Performance3.35%-0.24%1.39%0.59%1 Month Performance20.49%-2.90%2.78%-3.54%1 Year PerformanceN/A21.00%15.85%3.80% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics3.6672 of 5 stars$2.47+0.8%$12.75+416.2%N/A$182.91M$1.43M0.0070Positive NewsAVNSAvanos Medical2.1544 of 5 stars$12.07-2.9%N/A-34.4%$555.26M$687.80M35.504,040Upcoming EarningsShort Interest ↑Analyst RevisionBFLYButterfly Network2.5468 of 5 stars$2.27-3.0%$3.00+32.2%+185.5%$551.44M$82.06M-4.93460Insider TradeNews CoveragePositive NewsCBLLCeriBell2.1976 of 5 stars$14.93+0.5%$32.50+117.7%N/A$535.51M$65.44M0.00N/ANews CoverageKIDSOrthoPediatrics4.1316 of 5 stars$20.52-2.3%$37.00+80.3%-32.6%$498.37M$204.73M-16.68200Upcoming EarningsPositive NewsBBNXBeta BionicsN/A$10.05-9.8%$24.83+147.1%N/A$435.66M$65.12M0.00294TMCITreace Medical Concepts2.4344 of 5 stars$6.44-0.2%$9.93+54.2%-32.4%$405.01M$209.36M-6.50250Upcoming EarningsGap UpDCTHDelcath Systems2.8588 of 5 stars$11.34-2.5%$22.75+100.6%+123.7%$379.13M$37.21M-8.4060Short Interest ↑Positive NewsNPCENeuroPace3.8684 of 5 stars$10.54-2.3%$15.20+44.2%-15.6%$343.18M$79.91M-10.54170Upcoming EarningsShort Interest ↓CLPTClearPoint Neuro2.1002 of 5 stars$11.95-2.4%$25.00+109.2%+156.6%$334.36M$31.39M-17.32110Upcoming EarningsPositive NewsTCMDTactile Systems Technology2.9437 of 5 stars$13.45+0.9%$18.00+33.8%-3.6%$318.31M$292.98M19.21980Upcoming EarningsPositive News Related Companies and Tools Related Companies AVNS Alternatives BFLY Alternatives CBLL Alternatives KIDS Alternatives BBNX Alternatives TMCI Alternatives DCTH Alternatives NPCE Alternatives CLPT Alternatives TCMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CATX Stock Free CATX Stock Alerts